Valeant Pharmaceuticals International Inc (VRX) - Financial and Strategic SWOT Analysis Review
Valeant Pharmaceuticals International Inc (VRX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:
Valeant Pharmaceuticals International Inc (Valeant) develops, manufactures and markets several branded, over-the-counter (OTC) and generic drugs. The company also offers medical devices such as medical contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices. Valeant offers products in the areas of dermatology, neurology, eye health and branded generics. It offers a diverse mix of products in various regions across the world including the US, Canada, Australasia, Latin America, and Central and Eastern Europe. The company has manufacturing facilities in Canada, Mexico, the US and countries in Europe, North Africa, Asia and South America. Valeant is headquartered in Laval, Quebec, Canada.
Valeant Pharmaceuticals International Inc Key Recent Developments
Feb 28,2018: Valeant Announces Fourth-Quarter And Full-Year 2017 Financial Results
Nov 15,2017: Bausch + Lomb Helps To Recycle More Than One Million Units Of Contact Lens Materials Within First Year Of Launching The ONE By ONE Recycling Program
Nov 07,2017: Valeant Announces Third-Quarter 2017 Results
Sep 15,2017: Valeant Commits $200,000 to Support Hurricane Relief Efforts
Sep 05,2017: Québec Superior Court Grants Leave under Québec Securities Act in Valeant Pharmaceuticals Securities Class Action
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.
The profile contains critical company information including:
- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Valeant Pharmaceuticals International Inc (Valeant) develops, manufactures and markets several branded, over-the-counter (OTC) and generic drugs. The company also offers medical devices such as medical contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices. Valeant offers products in the areas of dermatology, neurology, eye health and branded generics. It offers a diverse mix of products in various regions across the world including the US, Canada, Australasia, Latin America, and Central and Eastern Europe. The company has manufacturing facilities in Canada, Mexico, the US and countries in Europe, North Africa, Asia and South America. Valeant is headquartered in Laval, Quebec, Canada.
Valeant Pharmaceuticals International Inc Key Recent Developments
Feb 28,2018: Valeant Announces Fourth-Quarter And Full-Year 2017 Financial Results
Nov 15,2017: Bausch + Lomb Helps To Recycle More Than One Million Units Of Contact Lens Materials Within First Year Of Launching The ONE By ONE Recycling Program
Nov 07,2017: Valeant Announces Third-Quarter 2017 Results
Sep 15,2017: Valeant Commits $200,000 to Support Hurricane Relief Efforts
Sep 05,2017: Québec Superior Court Grants Leave under Québec Securities Act in Valeant Pharmaceuticals Securities Class Action
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
SECTION 1 - ABOUT THE COMPANY
Valeant Pharmaceuticals International Inc - Key Facts
Valeant Pharmaceuticals International Inc - Key Employees
Valeant Pharmaceuticals International Inc - Key Employee Biographies
Valeant Pharmaceuticals International Inc - Major Products and Services
Valeant Pharmaceuticals International Inc - History
Valeant Pharmaceuticals International Inc - Company Statement
Valeant Pharmaceuticals International Inc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
SECTION 2 – COMPANY ANALYSIS
Company Overview
Valeant Pharmaceuticals International Inc - Business Description
Business Segment: Bausch + Lomb/International
Overview
Performance
Key Stats
Business Segment: Branded Rx
Overview
Performance
Business Segment: US Diversified Products
Overview
Performance
Geographical Segment: Australia
Performance
Geographical Segment: Brazil
Performance
Geographical Segment: Canada
Performance
Geographical Segment: China
Performance
Geographical Segment: Egypt
Performance
Geographical Segment: France
Performance
Geographical Segment: Germany
Performance
Geographical Segment: Japan
Performance
Geographical Segment: Mexico
Performance
Geographical Segment: Others
Performance
Geographical Segment: Poland
Performance
Geographical Segment: Russia
Performance
Geographical Segment: The UK
Performance
Geographical Segment: The US and Puerto Rico
Performance
R&D Overview
Valeant Pharmaceuticals International Inc - Corporate Strategy
Valeant Pharmaceuticals International Inc - SWOT Analysis
SWOT Analysis - Overview
Valeant Pharmaceuticals International Inc - Strengths
Valeant Pharmaceuticals International Inc - Weaknesses
Valeant Pharmaceuticals International Inc - Opportunities
Valeant Pharmaceuticals International Inc - Threats
Valeant Pharmaceuticals International Inc - Key Competitors
SECTION 3 – COMPANY FINANCIAL RATIOS
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts
SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES
Valeant Pharmaceuticals International Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
Valeant Pharmaceuticals International Inc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018
Valeant Pharmaceuticals International Inc, Recent Deals Summary
SECTION 5 – COMPANY’S RECENT DEVELOPMENTS
Nov 15, 2017: Bausch + Lomb Helps To Recycle More Than One Million Units Of Contact Lens Materials Within First Year Of Launching The ONE By ONE Recycling Program
Nov 07, 2017: Valeant Announces Third-Quarter 2017 Results
Sep 15, 2017: Valeant Commits $200,000 to Support Hurricane Relief Efforts
Sep 05, 2017: Québec Superior Court Grants Leave under Québec Securities Act in Valeant Pharmaceuticals Securities Class Action
Aug 16, 2017: Valeant Receives FDA Confirmation Of Voluntary Action Indicated Inspection Classification For Tampa Facility
Aug 08, 2017: Valeant Announces Second-Quarter 2017 Results
Jun 22, 2017: Bausch + Lomb Named Most Trusted Contact Lens Solution Brand In Canada For Second Consecutive Year By Brandspark International
Jun 22, 2017: Bausch + Lomb Named Most Trusted Contact Lens Solution Brand In Canada For Second Consecutive Year By Brandspark International
Jun 19, 2017: Valeant Appoints Arthur J. Shannon As Senior Vice President, Head Of Investor Relations And Communications
Jun 19, 2017: John Paulson Joins Valeant Board Of Directors
SECTION 6 – APPENDIX
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer
Valeant Pharmaceuticals International Inc - Key Facts
Valeant Pharmaceuticals International Inc - Key Employees
Valeant Pharmaceuticals International Inc - Key Employee Biographies
Valeant Pharmaceuticals International Inc - Major Products and Services
Valeant Pharmaceuticals International Inc - History
Valeant Pharmaceuticals International Inc - Company Statement
Valeant Pharmaceuticals International Inc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
SECTION 2 – COMPANY ANALYSIS
Company Overview
Valeant Pharmaceuticals International Inc - Business Description
Business Segment: Bausch + Lomb/International
Overview
Performance
Key Stats
Business Segment: Branded Rx
Overview
Performance
Business Segment: US Diversified Products
Overview
Performance
Geographical Segment: Australia
Performance
Geographical Segment: Brazil
Performance
Geographical Segment: Canada
Performance
Geographical Segment: China
Performance
Geographical Segment: Egypt
Performance
Geographical Segment: France
Performance
Geographical Segment: Germany
Performance
Geographical Segment: Japan
Performance
Geographical Segment: Mexico
Performance
Geographical Segment: Others
Performance
Geographical Segment: Poland
Performance
Geographical Segment: Russia
Performance
Geographical Segment: The UK
Performance
Geographical Segment: The US and Puerto Rico
Performance
R&D Overview
Valeant Pharmaceuticals International Inc - Corporate Strategy
Valeant Pharmaceuticals International Inc - SWOT Analysis
SWOT Analysis - Overview
Valeant Pharmaceuticals International Inc - Strengths
Valeant Pharmaceuticals International Inc - Weaknesses
Valeant Pharmaceuticals International Inc - Opportunities
Valeant Pharmaceuticals International Inc - Threats
Valeant Pharmaceuticals International Inc - Key Competitors
SECTION 3 – COMPANY FINANCIAL RATIOS
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts
SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES
Valeant Pharmaceuticals International Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
Valeant Pharmaceuticals International Inc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018
Valeant Pharmaceuticals International Inc, Recent Deals Summary
SECTION 5 – COMPANY’S RECENT DEVELOPMENTS
Nov 15, 2017: Bausch + Lomb Helps To Recycle More Than One Million Units Of Contact Lens Materials Within First Year Of Launching The ONE By ONE Recycling Program
Nov 07, 2017: Valeant Announces Third-Quarter 2017 Results
Sep 15, 2017: Valeant Commits $200,000 to Support Hurricane Relief Efforts
Sep 05, 2017: Québec Superior Court Grants Leave under Québec Securities Act in Valeant Pharmaceuticals Securities Class Action
Aug 16, 2017: Valeant Receives FDA Confirmation Of Voluntary Action Indicated Inspection Classification For Tampa Facility
Aug 08, 2017: Valeant Announces Second-Quarter 2017 Results
Jun 22, 2017: Bausch + Lomb Named Most Trusted Contact Lens Solution Brand In Canada For Second Consecutive Year By Brandspark International
Jun 22, 2017: Bausch + Lomb Named Most Trusted Contact Lens Solution Brand In Canada For Second Consecutive Year By Brandspark International
Jun 19, 2017: Valeant Appoints Arthur J. Shannon As Senior Vice President, Head Of Investor Relations And Communications
Jun 19, 2017: John Paulson Joins Valeant Board Of Directors
SECTION 6 – APPENDIX
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer
LIST OF TABLES
Valeant Pharmaceuticals International Inc, Key Facts
Valeant Pharmaceuticals International Inc, Key Employees
Valeant Pharmaceuticals International Inc, Key Employee Biographies
Valeant Pharmaceuticals International Inc, Major Products and Services
Valeant Pharmaceuticals International Inc, History
Valeant Pharmaceuticals International Inc, Other Locations
Valeant Pharmaceuticals International Inc, Subsidiaries
Valeant Pharmaceuticals International Inc, Key Competitors
Valeant Pharmaceuticals International Inc, Ratios based on current share price
Valeant Pharmaceuticals International Inc, Annual Ratios
Valeant Pharmaceuticals International Inc, Annual Ratios (Cont.1)
Valeant Pharmaceuticals International Inc, Annual Ratios (Cont.2)
Valeant Pharmaceuticals International Inc, Interim Ratios
Valeant Pharmaceuticals International Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
Valeant Pharmaceuticals International Inc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018
Valeant Pharmaceuticals International Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios
Valeant Pharmaceuticals International Inc, Key Facts
Valeant Pharmaceuticals International Inc, Key Employees
Valeant Pharmaceuticals International Inc, Key Employee Biographies
Valeant Pharmaceuticals International Inc, Major Products and Services
Valeant Pharmaceuticals International Inc, History
Valeant Pharmaceuticals International Inc, Other Locations
Valeant Pharmaceuticals International Inc, Subsidiaries
Valeant Pharmaceuticals International Inc, Key Competitors
Valeant Pharmaceuticals International Inc, Ratios based on current share price
Valeant Pharmaceuticals International Inc, Annual Ratios
Valeant Pharmaceuticals International Inc, Annual Ratios (Cont.1)
Valeant Pharmaceuticals International Inc, Annual Ratios (Cont.2)
Valeant Pharmaceuticals International Inc, Interim Ratios
Valeant Pharmaceuticals International Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
Valeant Pharmaceuticals International Inc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018
Valeant Pharmaceuticals International Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios
LIST OF FIGURES
Valeant Pharmaceuticals International Inc, Performance Chart (2013 - 2017)
Valeant Pharmaceuticals International Inc, Ratio Charts
Valeant Pharmaceuticals International Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
Valeant Pharmaceuticals International Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018
COMPANIES MENTIONED
AIM Therapeutics Inc
Endo International Plc
GTx Inc
Maruho Co Ltd
Mylan NV
Opiant Pharmaceuticals Inc
Pfizer Canada Inc
Polydex Pharmaceuticals Ltd
Sirona Biochem Corp
Stratus Pharmaceuticals Inc
Xenon Pharmaceuticals Inc
Valeant Pharmaceuticals International Inc, Performance Chart (2013 - 2017)
Valeant Pharmaceuticals International Inc, Ratio Charts
Valeant Pharmaceuticals International Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
Valeant Pharmaceuticals International Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018
COMPANIES MENTIONED
AIM Therapeutics Inc
Endo International Plc
GTx Inc
Maruho Co Ltd
Mylan NV
Opiant Pharmaceuticals Inc
Pfizer Canada Inc
Polydex Pharmaceuticals Ltd
Sirona Biochem Corp
Stratus Pharmaceuticals Inc
Xenon Pharmaceuticals Inc